Phenylethyl isovalerate

A repeated-dose oral toxicity study evaluates systemic toxic effects after daily oral exposure to a test substance for a defined period, commonly 28 days, 6 weeks, 90 days, or 13 weeks in rodent studies. The readout is generated by integrating mortality, clinical signs, body-weight change, food and water intake, functional or behavioral observations, hematology, serum biochemistry, urinalysis, organ weights, necropsy, and histopathology to identify dose-related adverse effects, target organs, and the no-observed-adverse-effect level (NOAEL).

This protocol evaluates hepatotoxicity using complementary in vivo mouse APAP acute liver injury and in vitro hepatocyte-based cytotoxicity readouts. In vivo APAP injury is assessed by serum ALT/AST, liver histology, hepatic glutathione, protein adducts, necrosis, inflammation, and regeneration-related endpoints. In vitro hepatotoxicity is assessed by loss of viability, leakage of ALT/AST/LDH, oxidative-stress markers, mitochondrial function, nuclear morphology, intracellular calcium, and high-content imaging endpoints.